Tilbake til: Farma og medisin
Innlegg av: Frontmasta (16.05.17 10:20 ), lest 13522 ganger
Ticker: NANO

NANO. Betalutin and Lugano news.

will be present...........

Upon submission of an abstract, the first author/presenter is responsible for........Certifying that the same abstract has neither been nor will be previously published before the 14-ICML.
Updated analyses must substantially differ from previously published manuscripts.

Special sessions devoted to radiotherapy are organized in collaboration with ILROG (International Lymphoma Radiation Oncology Group): a first satellite workshop open to all 14-ICML attendees and a second one open to radiation oncologists only will possibly take place. Details will be available closer to the event at www.lymphcon.ch. A special session on “Contouring in Modern Lymphoma Radiotherapy Planning” will be held on Saturday June 17 for max. 30 lymphoma radiation oncologists

New drug development - number 282

http://www.lymphcon.ch/icml/website/doc/14-ICML_accepted_abstracts_list.pdf



Fast Track

http://lymphobob.blogspot.no/2017/04/

RIT

https://www.ncbi.nlm.nih.gov/pubmed/28491264


chHH1 humanized version of the murine HH1 antibody

http://www.google.ch/patents/US20140348745